We are live on ! Find out more
ABVX icon

Abivax

250 hedge funds and large institutions have $7.61B invested in Abivax in 2025 Q4 according to their latest regulatory filings, with 110 funds opening new positions, 76 increasing their positions, 50 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

358% more first-time investments, than exits

New positions opened: 110 | Existing positions closed: 24

63% more capital inflows, than outflows

Capital inflows: $1.36B | Capital outflows: $834M

62% more funds holding in top 10

Funds holding in top 10: 21 → 34 (+13)

52% more repeat investments, than reductions

Existing positions increased: 76 | Existing positions reduced: 50

52% more funds holding

Funds holding: 165 → 250 (+85)

50% more call options, than puts

Call options by funds: $341M | Put options by funds: $228M

5.15% more ownership

Funds ownership: 67.11% → 72.26% (+5.1%)

Holders
250
Holders Change
+85
Holders Change %
+51.52%
% of All Funds
3.01%
Holding in Top 10
34
Holding in Top 10 Change
+13
Holding in Top 10 Change %
+61.9%
% of All Funds
0.41%
New
110
Increased
76
Reduced
50
Closed
24
Calls
$341M
Puts
$228M
Net Calls
+$113M
Net Calls Change
+$111M

ABVX Hedge Fund Activity: Q4 2025 in Review

250 of the 8,315 institutional investors tracked by Wall St. Rank reported a position in Abivax (ABVX) for Q4 2025, worth a combined $7.61B — up 73% from $4.41B a quarter earlier.

Buyers outnumbered sellers: 110 funds opened new ABVX positions and 24 closed out — a net gain of 86 holders — while 76 added to existing stakes and 50 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $183M. The largest seller was Cormorant Asset Management, cutting an estimated $65.5M.

  • 250 institutional investors held Abivax (ABVX) as of Q4 2025, up from 165 in Q3 2025.
  • Funds reported $7.61B of Abivax stock for Q4 2025, up 73% quarter-over-quarter.
  • 110 funds opened new Abivax positions in Q4 2025 and 24 closed out, a net change of +86 holders.
  • The largest Abivax buyer in Q4 2025 was Morgan Stanley, an estimated $183M added.
  • The largest Abivax seller in Q4 2025 was Cormorant Asset Management, an estimated $65.5M sold.

Based on aggregated 13F filings for Q4 2025.